Hypotension News and Research RSS Feed - Hypotension News and Research

New drug receives FDA approval to reduce risk of cardiovascular death in adults with diabetes

New drug receives FDA approval to reduce risk of cardiovascular death in adults with diabetes

The U.S. Food and Drug Administration today approved a new indication for Jardiance (empagliflozin) to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease. [More]
Newcastle scientists develop promising new test to identify patients with rare liver disease

Newcastle scientists develop promising new test to identify patients with rare liver disease

Newcastle scientists and medics have developed a promising new test to identify patients with a rare liver disease who will not respond to standard treatment, allowing earlier intervention with alternatives. [More]
Upright posture in patients with Parkinson's disease exacerbates cognitive deficits, study shows

Upright posture in patients with Parkinson's disease exacerbates cognitive deficits, study shows

In a new study published online today in the journal Neurology, a research team led by neurologists at Beth Israel Deaconess Medical Center and neuropsychologists at Boston University has shown that when patients with Parkinson's disease experience a drop in blood pressure upon standing up - a condition known as orthostatic hypotension (OH) - they exhibit significant cognitive deficits. [More]
Pennsylvania hospitals reduce mortality rates for ten common health conditions, new report reveals

Pennsylvania hospitals reduce mortality rates for ten common health conditions, new report reveals

Pennsylvania hospitals continue to improve quality and drive down mortality and readmission rates according to a new report released today by the Pennsylvania Health Care Cost Containment Council (PHC4). [More]
New review looks at complexity of fracture epidemiology in diabetes

New review looks at complexity of fracture epidemiology in diabetes

Due to the ageing of populations as well as increasing obesity and adverse lifestyle factors, type 2 diabetes (T2D) is reaching epidemic proportions in many parts of the world. [More]
Good blood microcirculation linked to longevity

Good blood microcirculation linked to longevity

Human longevity has been previously linked by researchers to genetic factors, calorie restriction, and certain life-style factors such as physical activity or the Mediterranean diet. [More]
European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

Amgen has announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. The extended indication marks the second approval for Kyprolis by the EC in less than a year. [More]
Antihypertensives prescribed for older adults despite having low blood pressure, study shows

Antihypertensives prescribed for older adults despite having low blood pressure, study shows

According to a new study in the journal Age and Ageing, a significant proportion of patients over 70 remain on antihypertensive medication despite having low blood pressure. [More]
Normoglycaemia key to improved neurological outcome after paediatric stroke

Normoglycaemia key to improved neurological outcome after paediatric stroke

Achieving normal blood glucose concentrations may be important in preventing poor neurological outcomes in children following acute arterial ischemic stroke, a retrospective review indicates. [More]
Aliskiren fails to show benefit for heart failure patients with diabetes

Aliskiren fails to show benefit for heart failure patients with diabetes

A subgroup analysis in heart failure patients with diabetes from the ATMOSPHERE trial has failed to show benefit and signals the end of the road for aliskiren in heart failure. [More]
SPRINT supports stringent BP goals for elderly

SPRINT supports stringent BP goals for elderly

Analysis of SPRINT participants older than 75 years shows that they too benefitted from an intensive blood pressure target of 120 mmHg. [More]
New set of practice guidelines from WMS may help in treatment, prevention of drowning

New set of practice guidelines from WMS may help in treatment, prevention of drowning

Drowning is a global threat to human health. Each year, more than 372,000 people die as a result of drowning, with many of those deaths being preventable by simple water safety measures. In order to arm professionals with the most up-to-date clinical protocols, the Wilderness Medical Society has issued a new set of practice guidelines for both the treatment and prevention of drowning, published in the society's official journal, Wilderness and Environmental Medicine. [More]
Researchers observe worrisome increase in anaphylaxis rate

Researchers observe worrisome increase in anaphylaxis rate

Anaphylaxis, known to be a sudden and potentially life-threatening allergic reaction, seems to be increasing among children, according to a new study led by a team at the Research Institute of the McGill University Health Centre. [More]
Pediatric researchers develop minimally invasive techniques to treat plastic bronchitis

Pediatric researchers develop minimally invasive techniques to treat plastic bronchitis

Pediatric researchers have devised an innovative, safe and minimally invasive procedure that helps relieve rare but potentially life-threatening airway blockages occurring in children who had surgery for congenital heart defects. [More]
Entresto drug shows added benefit in symptomatic chronic heart failure

Entresto drug shows added benefit in symptomatic chronic heart failure

The fixed-dose combination of sacubitril and valsartan (trade name: Entresto) has been approved since November 2015 for adults with symptomatic chronic heart failure with reduced pump function (ejection fraction). The German Institute for Quality and Efficiency in Health Care (IQWiG) now examined in an early benefit assessment whether this drug combination offers an added benefit for patients in comparison with the appropriate comparator therapy. [More]
FDA approves Defitelio to treat hepatic veno-occlusive disease in adults, children

FDA approves Defitelio to treat hepatic veno-occlusive disease in adults, children

The U.S. Food and Drug Administration today approved Defitelio (defibrotide sodium) to treat adults and children who develop hepatic veno-occlusive disease (VOD) with additional kidney or lung abnormalities after they receive a stem cell transplant from blood or bone marrow called hematopoietic stem cell transplantation (HSCT). [More]
Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Amgen and UCB today announced top-line results from the Phase 3 placebo-controlled FRActure study in postmenopausal woMen with ostEoporosis (FRAME). [More]
Promising phase II results for ozanimod in MS

Promising phase II results for ozanimod in MS

The selective sphingosine 1-phosphate receptor inhibitor ozanimod significantly reduces lesion activity in patients with relapsing-remitting multiple sclerosis, shows a phase II study published in The Lancet Neurology. [More]
Basaglar (insulin glargine injection) approved to improve glycemic control in diabetes patients

Basaglar (insulin glargine injection) approved to improve glycemic control in diabetes patients

The U.S. Food and Drug Administration today approved Basaglar (insulin glargine injection), a long-acting human insulin analog to improve glycemic control in adult and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. [More]
Bridion injection approved to reverse effects of neuromuscular blocking drugs used during certain types of surgery

Bridion injection approved to reverse effects of neuromuscular blocking drugs used during certain types of surgery

The U.S. Food and Drug Administration today approved Bridion (sugammadex) injection to reverse the effects of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide, which are used during certain types of surgery in adults. [More]
Advertisement
Advertisement